Incyte

Traded on the St. Petersburg Stock Exchange
Incyte Corp is an American multinational pharmaceutical company.
Incyte stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Incyte balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Incyte cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Incyte multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Incyte profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Incyte assets
Incyte cash flows

Incyte shares

TickerNameTypeNominal valueISINPrice
INCY:USIncyte CorporationCommon share-US45337C1027$66.17
Incyte news
03.05.2022
Incyte's GAAP net income for 3 months of 2022 was $37.992 million, down 29% from $53.535 million in the previous year. Revenue rose 21.3% to $733.235 million from $604.718 million a year earlier.
Source: {source} pictogram sec.gov
08.02.2022
Incyte's GAAP net income for 2021 was $948.581 million, compared to a loss of $295.697 million in the previous year. Revenue increased 12% to $2.986 billion from $2.667 billion a year earlier.
02.11.2021
Incyte's GAAP net income for 9M 2021 amounted to $384.73 mln, against a loss of $445.547 mln in the previous year. Revenue increased 13.1% to $2.123 billion from $1.877 billion a year earlier.
22.09.2021
Incyte has received FDA approval for its Opzelura cream. It is for the treatment of mild to moderate chronic atopic dermatitis in non-immunocompromised patients 12 years of age and older.
General information
Company nameIncyte
Tags#biotechnology, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 3024986700
Mailing address1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Websitewww.incyte.com
Information disclosurewww.sec.gov